UNIVERSAL STABILIZATION TECHNOLOGIES, INC.

Biotech · Private

Thermostable, inactivated Yellow Fever vaccine using Preservation by Vaporization (PBV) technology and electron beam inactivation

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$7.9M
Federal grants
$3.7M
8 awards · 2015–2022
Rank in peer group#181 of 326
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$4.2M
11 awards · Defense, Health and Human S
Rank in Biotech#93 of 4373
Granted patents
4
7 pending · first 2017
Rank in peer group#35 of 326

Capital timeline

20052009201320172021FEDERAL ↑EQUITY ↓Cumulative $7.9M$848K$999K$1.3M$1.0M$816K
20052009201320172021FEDERAL ↑EQUITY ↓Cumulative $7.9M$848K$999K$1.3M$1.0M

Latest events

  • Federal grantHealth and Human S · Phase I · Thermostable Inactivated Potent Yellow Fever Vaccine$297K
  • Federal grantHealth and Human S · Phase I · Thermostable Inactivated Potent Yellow Fever Vaccine$299K
  • Federal grantHealth and Human S · Phase I · Development of a thermostable, electron beam inactivated Sabin-based polio vaccine for mucosal delivery$222K
  • Federal grantHealth and Human S · Phase I · Development of a thermostable, electron beam inactivated Sabin-based polio vaccine for mucosal delivery$222K
  • Federal contractHealth and Human S · Igf::ot::igf Adjuvant Development For A Thermostable Respiratory Influenza Vaccine$600K
  • Federal grantHealth and Human S · Phase II · Development of a thermostable rotavirus vaccine for mucosal delivery withoutneed for reconstitution - Phase II$816K
  • Federal contractHealth and Human S · SBIR Phase II Topic 32 Ncird Igf::ot::igf For Other Functions$1.0M
Show 12 earlier federal awards
  • Federal grantHealth and Human S · Phase II · Development of a thermostable rotavirus vaccine for mucosal delivery withoutneed for reconstitution - Phase II$1.3M
  • Federal grantHealth and Human S · Phase II · Development of a thermostable rotavirus vaccine for mucosal delivery withoutneed for reconstitution - Phase II$455K
  • Federal contractHealth and Human S · Services$150K
  • Federal contractHealth and Human S · Igf::ot::igf$20K
  • Federal contractHealth and Human S · Pplb Sabin Ipv Stabilization Project Igf::ot::igf For Other Functions$200K
  • Federal contractHealth and Human S · Ust Thermostable Life Attenuated Influenza Vaccine Igf::ot::igf For Other Functions$25K
  • Federal grantHealth and Human S · Phase I · Development of a thermostable rotavirus vaccine for mucosal delivery without need for reconstitution$148K
  • Federal contractHealth and Human S · Igf::cl::igf$150K
  • Federal contractHealth and Human S · Igf::ot::igf SBIR Phase II$999K
  • Federal contractHealth and Human S · SBIR Thermostoppable Measles$100K
  • Federal contractDefense · SBIR Phase 1 Rad II/USAISR/A083-176-0149$70K
  • Federal contractDefense · 200512!503113!2100!W81XWH!US Army Medical Research Acq ACT!W81XWH05C0164 !a!n! !n! ! !20050812!20060714!129102708!129102708!129102708!N!UNIVERSAL Stabilization TECHNO!4050 Sorrento Valley Blvd !san Diego !CA!92121!66000!073!06!SAN Diego !san Diego !CALIFORNIA!+000000098817!N!N!000000098817!AN11!RDTE/BIOMEDICAL - Basic Research !S1 !services !000 !* !541710!E! !3! ! ! ! ! !202$848K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 326 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median
  • Granted patents#35 · top 11%
  • Linked publications#28 · top 9%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 4 granted of 11
  • PendingThermostable Uv Inactivated Vaccines And Other BiopharmaceuticalsUSPTOApplication 18840732
  • PendingInactivated Vaccines & Nucleic Acid Aptamer Therapeutics Derived TherefromUSPTOApplication 17313798
  • GrantedMethod For Preserving BiopharmaceuticalsUSPTOUS 11,400,051
Show all 11 patent records

Recent research by its founders

  • Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets202118 cites
  • Thermostable, Dissolvable Buccal Film Rotavirus Vaccine Is Highly Effective in Neonatal Gnotobiotic Pig Challenge Model202116 cites
  • Inactivated Rabies Virus–Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge201919 cites

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .